Syros falls on Phase II AML, MDS data

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) lost $3.92 (32%) to $8.45 on Monday after reporting that only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to treat relapsed or refractory acute myelogenous leukemia and myelodysplastic syndrome. The data were presented at the American Society of Hematology meeting in Atlanta. Syros said it does not plan to pursue further development of tamibarotene as a single agent.

The trial enrolled AML and MDS patients who were positive for the retinoic acid receptor alpha (RARA) and/or interferon regulatory factor 8 (IRF8) biomarkers. The evaluable patients were split amongst two cohorts -- one comprising 23 patients with relapsed or refractory AML or high-risk MDS and another comprising 25 patients with low-risk transfusion-dependent MDS...